New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients
Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco Burzotta and colleagues on data from the Roma-Verona Registry. This study examined the long-term outcomes of complex high-risk patients with multivessel disease who were considered unsuitable for surgery and received an Impella-supported Protected PCI.
Dr. Burzotta and colleagues conducted this two-center retrospective study using a prospectively maintained registry database and studied the long-term outcomes of 86 complex high-risk indicated patients (CHIP) undergoing Impella-protected PCI from 2007 through 2016. Of these patients, using a heart team approach, 100% were deemed too high-risk for open heart surgery. The mean age of these patients was 72 years, 70% had a NYHA class 3 or 4 heart failure symptoms, 78% had a left ventricular ejection fraction, or EF, of less than 35%. And while all had multi-vessel disease, 44% had left main coronary artery disease.
The study found that six months after Protected PCI, the number of patients with EF greater than or equal to 35% increased by three times or 205%, from 22% of the patients to 67% of the patients at 6 months. The study also found more complete revascularization was associated with significant EF improvement and survival. These data corroborate other results seen the United States as well as the Protect II randomized controlled trial.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information